Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9840505
APP PUB NO 20160152619A1
SERIAL NO

15016117

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INFINITY PHARMACEUTICALS INC1100 MASSACHUSETTS AVE CAMBRIDGE MA 02138

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Isbester, Paul Castleton, US 14 118
Kropp, Jason Westford, US 7 100
Lane, Benjamin S Lynnfield, US 10 100
Martin, Michael San Marcos, US 151 1750
Ren, Pingda San Diego, US 198 6390

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 12, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 12, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00